GSK650394

For research use only.

Catalog No.S7209

19 publications

CAS No. 890842-28-1

GSK650394 is a serum- and glucocorticoid-regulated kinase-1 inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2, respectively.

Selleck's GSK650394 has been cited by 19 publications

SLAS Discov, 2021, 24725552211002465

PubMed: 33783250 ( click the link to review the publication )

Biomedicines, 2021, 9(1)E33

PubMed: 33406639 ( click the link to review the publication )

Sci Adv, 2020, 6(50)eabc8096

PubMed: 33298440 ( click the link to review the publication )

Neuropsychopharmacology, 2020, 10.1038/s41386-020-00924-0

PubMed: 33288841 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

J Mol Med (Berl), 2019, 10.1007/s00109-019-01807-8

PubMed: 31187175 ( click the link to review the publication )

Front Physiol, 2019, 10:167

PubMed: 30873046 ( click the link to review the publication )

Am J Transl Res, 2019, 11(8):4946-4956

PubMed: 31497211 ( click the link to review the publication )

Int J Clin Exp Pathol, 2019, 12(2):391-408

PubMed: 31933845 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 2;37(1):73

PubMed: 29609629 ( click the link to review the publication )

Br J Cancer, 2017, 117(8):1139-1153

PubMed: 29017179 ( click the link to review the publication )

Cell Death Dis, 2017, 8(2):e2574

PubMed: 28151476 ( click the link to review the publication )

Int J Biol Sci, 2017, 13(4):434-448

PubMed: 28529452 ( click the link to review the publication )

Cancer Res, 2017, 77(24):6914-6926

PubMed: 29055016 ( click the link to review the publication )

Virus Res, 2016, 222:106-112

PubMed: 27297663 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45715-45729

PubMed: 27304189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):53-59

PubMed: 27457803 ( click the link to review the publication )

Purity & Quality Control

Choose Selective SGK Inhibitors

Biological Activity

Description

GSK650394 is a serum- and glucocorticoid-regulated kinase-1 inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2, respectively.

Targets

SGK1 ^[1] (Cell-free assay)	SGK2 ^[1] (Cell-free assay)
62 nM	103 nM

In vitro

GSK650394 inhibits SGK1-mediated epithelial transport with an IC50 of 0.6 μM in the SCC assay. In LNCaP cells, GSK650394 inhibits the androgen-mediated enhancement of Nedd4-2 phosphorylation and androgen-mediated cell growth. ^[2] GSK650394 counteracts the Cortisol-induced decrease in neurogenesis, changes in Hedgehog signaling, and GR nuclear translocation. [2] GSK 650394 inhibits replication of influenza virus by impairing the export of influenza vRNPs into the cytoplasm of A549 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
human M-1 cells	MnzISpVv[3Srb36gZZN{[Xl?	NVq0SVl7UW6qaXLpeIlwdiCxZjDTS2syNW2nZHnheIVlKGWyaYTo[Yxq[Wxic3;kbZVuKGOqYX7u[Ywh[WO2aY\peJkhcW5iaIXtZY4hVS1zIHPlcIx{KGG\|c3Xzd4VlKGG\|IIPoc5J1KGOrcnP1bZQh[3W{cnXueEBjgSC5aH;s[UBk\WyuIHXs[YN1em:yaInzbY9td2erY3HsJJRz[W6\|ZYDpeIhmdGmjbDDlfJBmemmvZX70MEBKSzVyPUCuOVgh\|ryP	MYixPVQ6Pzd2NR?=
human MV-4-11 cell	NFS3cHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2H1fWlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTZ2OTFOwG0>	M1i2dnNCVkeHUh?=
human Daoy cell	NX[1NVNsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYfIS2tGUW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42OTV\|MjFOwG0>	NGHuWZVUSU6JRWK=
human BFTC-905 cell	NYjOU\|JiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MWPJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44QDR3NTFOwG0>	MVnTRW5ITVJ?
human KM12 cell	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGtOOTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki1NFY6KM7:TR?=	NW\O[5pVW0GQR1XS
human GDM-1 cell	MlTwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NI[yRnNKdmirYnn0bY9vKG:oIHj1cYFvKEeGTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45Pzl\|NzFOwG0>	MlfwV2FPT0WU
human RT-112 cell	NVmxPIZGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYnJcohq[mm2aX;uJI9nKGi3bXHuJHJVNTFzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFI4QDJizszN	NInrUGZUSU6JRWK=
human MONO-MAC-6 cell	M3fIS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{W3cWlvcGmkaYTpc44hd2ZiaIXtZY4hVU:QTz3NRWMuPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwMUiwPVch\|ryP	NE\WRXNUSU6JRWK=
human HUTU-80 cell	NHrqT2pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3;mXmlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzBzN{Kg{txO	M3nLSnNCVkeHUh?=
human HGC-27 cell	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGhISy1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|A5OjFizszN	MoDHV2FPT0WU
human LCLC-97TM1 cell	NGPuRnVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYDJcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvOUfUUVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjN4N{[4JO69VQ>?	MnPqV2FPT0WU
human LXF-289 cell	MnjuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M{L6XmlvcGmkaYTpc44hd2ZiaIXtZY4hVFiILUK4PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDBzNUKg{txO	MlSwV2FPT0WU
human HLE cell	NFPTfYZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MVPJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwNEK2PFMh\|ryP	MkSzV2FPT0WU
human RKO cell	M4rwemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M2OzUGlvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT61O\|g3QSEQvF2=	NXXGPYtuW0GQR1XS
human SNG-M cell	NGXlW49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NVSxWHd7UW6qaXLpeIlwdiCxZjDoeY1idiCVTletUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzl6NUOg{txO	M3jRenNCVkeHUh?=
human MCF7 cell	NYrFdG5HT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MV3Jcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkixO\|gh\|ryP	NHnIdWtUSU6JRWK=
human A431 cell	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1[1cGlvcGmkaYTpc44hd2ZiaIXtZY4hSTR\|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPFU6ODJizszN	MnSxV2FPT0WU
human BC-3 cell	NFzYVIpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWTJcohq[mm2aX;uJI9nKGi3bXHuJGJENTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLki3NFk1KM7:TR?=	NVfKRWNWW0GQR1XS
human A427 cell	M2KzUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NETPSZhKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg4PjFzIN88US=>	MYrTRW5ITVJ?
human SW620 cell	MmOxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3HNXGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d4MkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlkzQDF4IN88US=>	MoXwV2FPT0WU
human HOS cell	NFfiUo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MorSTY5pcWKrdHnvckBw\iCqdX3hckBJV1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkm3N\|EzKM7:TR?=	MWnTRW5ITVJ?
human MFH-ino cell	M2S5b2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXT4WGRYUW6qaXLpeIlwdiCxZjDoeY1idiCPRlitbY5wKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS57OE[1PEDPxE1?	M1yxfXNCVkeHUh?=
human TE-12 cell	NHe5SFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NFXPNnBKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46QTF{ODFOwG0>	NF2wSVFUSU6JRWK=
human KU812 cell	Mn7FS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVrpNGZPUW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOTh5MTFOwG0>	M{K5TnNCVkeHUh?=
human NCI-H2342 cell	MonES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXTLe21lUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI{PDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkG5NFU{KM7:TR?=	MWDTRW5ITVJ?
human BC-1 cell	NYO4TXpYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXu5N3BPUW6qaXLpeIlwdiCxZjDoeY1idiCEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42OTZ3MTFOwG0>	MYHTRW5ITVJ?
human TE-15 cell	M2jsfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXLJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTF3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj61PVE5OSEQvF2=	MV3TRW5ITVJ?
human T84 cell	MlTOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NU\KcIlvUW6qaXLpeIlwdiCxZjDoeY1idiCWOESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlYxPDR4IN88US=>	M2\3enNCVkeHUh?=
human SW1710 cell	M1zzTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NVfCb5VTUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjdyMEiyJO69VQ>?	NWi5c5pRW0GQR1XS
human CAL-12T cell	NUjVd\|VWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MkjBTY5pcWKrdHnvckBw\iCqdX3hckBESUxvMULUJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44OTF3ODFOwG0>	M1LhNXNCVkeHUh?=
human NKM-1 cell	NYDMW4dwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M3zjNWlvcGmkaYTpc44hd2ZiaIXtZY4hVkuPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlc3PzNzIN88US=>	MVvTRW5ITVJ?
human OCUB-M cell	NGnO[GhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1TCV2lvcGmkaYTpc44hd2ZiaIXtZY4hV0OXQj3NJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44QDh4MTFOwG0>	NV7vb3dIW0GQR1XS
human 786-0 cell	NWr4eFhWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVPSbYV5UW6qaXLpeIlwdiCxZjDoeY1idiB5OE[tNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQTR6MkWg{txO	MnzpV2FPT0WU
human EW-13 cell	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXrJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz6wNVU2QCEQvF2=	MmDVV2FPT0WU
human 5637 cell	M3;C[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXfJcohq[mm2aX;uJI9nKGi3bXHuJFU3OzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|LkKwOlY6KM7:TR?=	M3PsV3NCVkeHUh?=
human PA-1 cell	NYn4R3VVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MV\Jcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|LkOzNFg{KM7:TR?=	M2LzTHNCVkeHUh?=
human NCI-H2122 cell	M4fOXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{jZTGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5\|M{Og{txO	NF7QV29USU6JRWK=
human NCI-H460 cell	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFLUdZVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOFYxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy52MESxJO69VQ>?	M4jYbXNCVkeHUh?=
human CHL-1 cell	NFv4eGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2Poe2lvcGmkaYTpc44hd2ZiaIXtZY4hS0iOLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ6PjZ3IN88US=>	Mn;RV2FPT0WU
human MOLT-16 cell	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFfQRpRKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjVzNUW1JO69VQ>?	Mn\HV2FPT0WU
human HCT-15 cell	MoD1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M{L5[WlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUG1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43Ojh2MjFOwG0>	M1X6WnNCVkeHUh?=
human G-361 cell	NG\ROYdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NHviPYlKdmirYnn0bY9vKG:oIHj1cYFvKEdvM{[xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44OTd2NTFOwG0>	Moe3V2FPT0WU
human SK-LU-1 cell	NGTNbmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3rsXGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTGWtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTdyMUSg{txO	M{TKbHNCVkeHUh?=
human ES4 cell	M2LH[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NYPI[II{UW6qaXLpeIlwdiCxZjDoeY1idiCHU{SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlA3ODZ7IN88US=>	NH24NlZUSU6JRWK=
human TE-8 cell	NIHjR2JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2nVS2lvcGmkaYTpc44hd2ZiaIXtZY4hXEVvODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNVE2QDJizszN	MYDTRW5ITVJ?
human IGR-1 cell	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mom2TY5pcWKrdHnvckBw\iCqdX3hckBKT1JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNlM{KM7:TR?=	NECx[JJUSU6JRWK=
human SW954 cell	NHXido1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M17uT2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlQ3OTJ2IN88US=>	M1vaNHNCVkeHUh?=
human A375 cell	MnjzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M1j5cmlvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuNlU1QTJizszN	NHPheWxUSU6JRWK=
human CAL-27 cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXLJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuN\|MzOjFizszN	Moi1V2FPT0WU
human CAL-51 cell	NHHOZopIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MUHJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuN\|U2QDNizszN	MmPtV2FPT0WU
human SK-LMS-1 cell	NV62Xmw3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MXTJcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyPUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{QDJ3NTFOwG0>	MkL2V2FPT0WU
human HT-1080 cell	NVf3eXFPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWrLfFB2UW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS52OUO0O{DPxE1?	NEnPUHdUSU6JRWK=
human NCI-H1299 cell	NUHveWFTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MXvJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUK5PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTh3NUeg{txO	MmXCV2FPT0WU
human HT-29 cell	NFTocW9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NY\MdIg6UW6qaXLpeIlwdiCxZjDoeY1idiCKVD2yPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOjZ6NEOg{txO	M4T5VHNCVkeHUh?=
human A388 cell	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXrJcohq[mm2aX;uJI9nKGi3bXHuJGE{QDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkW5PVY2KM7:TR?=	NW[welBUW0GQR1XS
human SK-MEL-30 cell	M1PXbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3fJcmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py57N{KxOUDPxE1?	MWnTRW5ITVJ?
human CMK cell	M2fz[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NH\vRmZKdmirYnn0bY9vKG:oIHj1cYFvKEOPSzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUiuNlU{PzdizszN	NVnjboZHW0GQR1XS
human HuP-T4 cell	MkfvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NETEOlNKdmirYnn0bY9vKG:oIHj1cYFvKEi3UD3UOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgvPTB{M{Sg{txO	NGHQT29USU6JRWK=
human SF126 cell	NXPK[XlZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NESyN45KdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE45ODJyODFOwG0>	NGDBWXJUSU6JRWK=
human MKN1 cell	NWK3cIJxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MXnJcohq[mm2aX;uJI9nKGi3bXHuJG1MVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17LkG4OVY2KM7:TR?=	MoLTV2FPT0WU
human LoVo cell	MmDCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NUiyR3hkUW6qaXLpeIlwdiCxZjDoeY1idiCOb2\vJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU46OTJ7MjFOwG0>	MWLTRW5ITVJ?
human HEL cell	NGO2dZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NW\iWpBrUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNE43QCEQvF2=	NX;LPVdRW0GQR1XS
human SW872 cell	MoXNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mm\QTY5pcWKrdHnvckBw\iCqdX3hckBUXzh5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGzMlY5QTZizszN	NEf5dFZUSU6JRWK=
human SW982 cell	M16z[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NWmyV457UW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE{Njd7MU[g{txO	NF;x[XlUSU6JRWK=
human HuH-7 cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MojITY5pcWKrdHnvckBw\iCqdX3hckBJfUhvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUG4MlI4QDNizszN	MYHTRW5ITVJ?
human DU-145 cell	M2rVbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MofaTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNE41QTV3IN88US=>	NGnP[IhUSU6JRWK=
human MC116 cell	NWP4O2pwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NX23fpU3UW6qaXLpeIlwdiCxZjDoeY1idiCPQ{GxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIyNjJ4N{[g{txO	MYHTRW5ITVJ?
human H4 cell	NVXwcWtDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MljCTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJzLkSyOFQh\|ryP	M3LCNnNCVkeHUh?=
human SK-MEL-3 cell	NVvkTZp4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NGjMRYxKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzBwMEKyPEDPxE1?	M2rkfXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p21 / LC3 / p62 / PARP / Cleaved PARP ; PubMed: 29017179 Br J Cancer PC3 cells were treated as in b; LNCaP cells were treated with DMSO or 80 μm GSK650394 (GSK) for various time points (6, 24 and 48 h). Total protein lysates were collected for western blot against p21, LC3B, p62, PARP and cleaved (CL) PARP; GAPDH was used as a loading control. c-Jun / NRF2 ; PubMed: 31136958 Redox Biol Western blot analysis of c-JUN and NRF2 proteins in cervical cancer cells treated with or without GSK650394. Vinculin was used as a loading control. p-SGK1 / SGK1 ; PubMed: 30873046 Front Physiol Podocytes were exposed to 1, 2.5, 5, 10, or 20 μM GSK650394 for 24 h and then analyzed by immunoblot. p-SGK2 / SGK2 ; PubMed: 26392083 Sci Rep Western blot analysis of immunoprecipitated p-SGK2 T193 and FLAG-SGK2 from whole cell lysates in pcDNA/FLAG/SGK2-transfected ShP51 cells treated with GSK650394 (10 μM) for 30 and 60 min.	29017179 31136958 30873046 26392083
Immunofluorescence	LC3; PubMed: 29017179 Br J Cancer Immunofluorescence staining for LC3 puncta.	29017179
Growth inhibition assay	Cell viability; PubMed: 29017179 Br J Cancer Cell viability analysis using a CCK8 assay of prostate cancer cell lines after treatment with various concentrations of GSK650394 or vehicle alone for the indicated time periods. Data are the means of triplicate experiments. The results are expressed as the percentage of viable control cells treated with DMSO alone (vehicle).	29017179

Protocol

Kinase Assay:^[1]	- Collapse Scintillation proximity assay (SPA): SGK1 S422D (60–431 aa; 0.275 μg/mL final concentration) or SGK2 (0.875 μg/mL final concentration) are activated by PDK1 (1.1 μg/mL final concentration) in a buffer consisting of 50 mM Tris (pH 7.5), 0.1 mM EGTA, 0.1 mM EDTA, 10 mM MgCl₂, 0.1% β-mercaptoethanol, 1 mg/mL BSA, and ATP (final concentration of 0.15 mM) and incubated for 30 min at 30°C. SGK2 is prepared exactly as described for SGK1, except it corresponded to the full-length protein. A solution containing biotinylated CROSStide peptide at a final concentration of 75 μM and γ³²P-ATP corresponding to 2×10⁶ cpm is prepared in the reaction buffer. In a 96-well plate, 5 μL of GSK650394 is added to 25 μL of the activated enzyme mixture. To this, 20 μL of the CROSStide mixture is added and incubated for 1 h at room temperature. Next, 50 μL of a 25 mg/mL slurry of streptavidin-coated SPA beads in PBS with 0.1 M EDTA, pH 8.0 is added. The plate is then sealed and centrifuged for 8 min at 2000 rpm, and the signal is detected by measuring for 30 sec/well in a Packard TopCount NXT Scintillation Counter. The IC50 values of the inhibition of SGK1 and SGK2 activities by GSK650394 are calculated from these data using GraphPad Prism 3 Software.
Cell Research:^[1]	- Collapse Cell lines: LNCaP cells Concentrations: ~10 μM Incubation Time: 7 days Method: LNCaP cells are plated at a density of 5,000 cells per well in 96-well plates in 100 μL PRF-RPMI 1640, supplemented with 8% CS-FBS, 0.1 mM NEAA, and 1 mM NaPyr. At day three, cells are treated with hormone with or without GSK650394 by removing 50 μL of the media and replacing this with 50 μL of PRF-RPMI 1640 with 8% CS-FBS, NEAA, NaPyr containing a 2X concentration of the appropriate hormone/inhibitor treatment. At days 5 and 7, the treatment is repeated. On the tenth day, the media is removed and the relative cell number is measured using the FluoReporter Blue assay according to the manufacturer’s instructions. (Only for Reference)

Kinase Assay:^[1]

- Collapse

Scintillation proximity assay (SPA):

SGK1 S422D (60–431 aa; 0.275 μg/mL final concentration) or SGK2 (0.875 μg/mL final concentration) are activated by PDK1 (1.1 μg/mL final concentration) in a buffer consisting of 50 mM Tris (pH 7.5), 0.1 mM EGTA, 0.1 mM EDTA, 10 mM MgCl₂, 0.1% β-mercaptoethanol, 1 mg/mL BSA, and ATP (final concentration of 0.15 mM) and incubated for 30 min at 30°C. SGK2 is prepared exactly as described for SGK1, except it corresponded to the full-length protein. A solution containing biotinylated CROSStide peptide at a final concentration of 75 μM and γ³²P-ATP corresponding to 2×10⁶ cpm is prepared in the reaction buffer. In a 96-well plate, 5 μL of GSK650394 is added to 25 μL of the activated enzyme mixture. To this, 20 μL of the CROSStide mixture is added and incubated for 1 h at room temperature. Next, 50 μL of a 25 mg/mL slurry of streptavidin-coated SPA beads in PBS with 0.1 M EDTA, pH 8.0 is added. The plate is then sealed and centrifuged for 8 min at 2000 rpm, and the signal is detected by measuring for 30 sec/well in a Packard TopCount NXT Scintillation Counter. The IC50 values of the inhibition of SGK1 and SGK2 activities by GSK650394 are calculated from these data using GraphPad Prism 3 Software.

Cell Research:^[1]

- Collapse

Cell lines: LNCaP cells
Concentrations: ~10 μM
Incubation Time: 7 days
Method: LNCaP cells are plated at a density of 5,000 cells per well in 96-well plates in 100 μL PRF-RPMI 1640, supplemented with 8% CS-FBS, 0.1 mM NEAA, and 1 mM NaPyr. At day three, cells are treated with hormone with or without GSK650394 by removing 50 μL of the media and replacing this with 50 μL of PRF-RPMI 1640 with 8% CS-FBS, NEAA, NaPyr containing a 2X concentration of the appropriate hormone/inhibitor treatment. At days 5 and 7, the treatment is repeated. On the tenth day, the media is removed and the relative cell number is measured using the FluoReporter Blue assay according to the manufacturer’s instructions.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	76 mg/mL (198.71 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download GSK650394 SDF

Molecular Weight	382.45
Formula	C₂₅H₂₂N₂O₂
CAS No.	890842-28-1
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1CCC(C1)C2=C(C=CC(=C2)C3=CNC4=C3C=C(C=N4)C5=CC=CC=C5)C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Choose Your Country or Region

By Signaling Pathways

By product type

GSK650394